An Open-label, Multi-arm, Non-comparative Safety and Tolerability Study of Canakinumab (ACZ885) in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)

Name: An Open-label, Multi-arm, Non-comparative Safety and Tolerability Study of Canakinumab (ACZ885) in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)
Published: 2013
License: Public Domain

Novartis Pharmaceuticals · 2013

ClinicalTrials.gov · Datasets · License: Public Domain · 2013

Open Source ↗

systemic juvenile idiopathic arthritis, sjia, children, systemic autoinflammatory disease, acz885, canakinumab, human monoclonal anti-interleukin-1β (il-1 β) antibody, hildhood immunizations vaccinations, interventional, phase3

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

An Open-label, Multi-arm, Non-comparative Safety and Tolerability Study of Canakinumab (ACZ885) in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)

Related documents